LRRK2 Degrader

XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC₅₀: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease.

JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 promotes ubiquitination and degradation of LRRK2. JH-XII-03-02 can be used for the research of Parkinson's disease.

CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC₅₀ of 9 nM.

PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC₅₀ of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation.

PROTAC LRRK2 Degrader-1 (compound 18) is a leucine-rich repeat kinase 2 (LRRK2) PROTAC degrader with an IC⁵⁰ value less than 10 nM. PROTAC LRRK2 Degrader-1 can be used in the research of Parkinson's disease.

PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC₅₀ of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation.

PROTAC LRRK2 Degrader-5 Formula (V) is a LRRK2 PROTAC degrader. PROTAC LRRK2 Degrader-5 can be used for thet study of the diseases associated with LRRK2, such as Parkinson’s Disease (PD).

PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting LRRK2 with a DC₅₀ of 0.14 nM. PROTAC LRRK2 Degrader-2 recruits LRRK2 or its mutants to the cereblon E3 ubiquitin ligase, thereby mediating the targeted ubiquitination and subsequent proteasomal degradation of LRRK2. PROTAC LRRK2 Degrader-2 can be used in research related to Parkinson's disease.